1 | times | 18,938 |
2 | hundred-fold | 5 |
3 | denvs | 4 |
4 | aul | 3 |
5 | ifets | 3 |
6 | l/head | 3 |
7 | uacrs | 3 |
8 | cans/pouches | 2 |
9 | group-meetings | 2 |
10 | hyperthyroidisms | 2 |
11 | kg/calf | 2 |
12 | kg/heifer | 2 |
13 | kj/kg/d | 2 |
14 | meq/litre | 2 |
15 | ms/cm | 2 |
16 | times-per-week | 2 |
17 | treatments/day | 2 |
18 | 0-1+ | 1 |
19 | 0.05/0.07 | 1 |
20 | 0.06/0.07 | 1 |
21 | 10-40-fold | 1 |
22 | 117.1j | 1 |
23 | 28-daycycles | 1 |
24 | 28.6-fold | 1 |
25 | 64·5 | 1 |
26 | 898-positive | 1 |
27 | acupuncturist-delivered | 1 |
28 | appendicovesicostomies | 1 |
29 | applications-a-day | 1 |
30 | arms.arm | 1 |
31 | badwas | 1 |
32 | bolus/20- | 1 |
33 | broodstocks | 1 |
34 | camcorders | 1 |
35 | cebidae | 1 |
36 | cef-patients | 1 |
37 | cis-epoxides | 1 |
38 | classifications-values | 1 |
39 | clpb/hsp100s | 1 |
40 | co5c | 1 |
41 | conditions-mahjong | 1 |
42 | cost-levels | 1 |
43 | cp-cases | 1 |
44 | cycle/degree | 1 |
45 | dabatases | 1 |
46 | dimensions-level | 1 |
47 | disulfide-bridges | 1 |
48 | domains-nad-binding | 1 |
49 | drinks/two | 1 |
50 | drugs/combination | 1 |
51 | départements | 1 |
52 | ep-hsps | 1 |
53 | euro2-6 | 1 |
54 | euro292 | 1 |
55 | fhps | 1 |
56 | g/head | 1 |
57 | g/kg-produced | 1 |
58 | g/twice | 1 |
59 | gbhsps | 1 |
60 | geq/l | 1 |
61 | gigatons | 1 |
62 | gm/hr | 1 |
63 | goats/group | 1 |
64 | groups-calcitriol | 1 |
65 | groups.patients | 1 |
66 | groups/blocks | 1 |
67 | hamuli | 1 |
68 | homeostasis-was | 1 |
69 | hsa-rois | 1 |
70 | hsp60s | 1 |
71 | hydroxy-3-methylglutaryl-coenzyme | 1 |
72 | inhibitor-meets | 1 |
73 | job-agencies | 1 |
74 | kg/m3-d. | 1 |
75 | kilobits | 1 |
76 | macronutrient-balanced | 1 |
77 | mailers | 1 |
78 | mestrua | 1 |
79 | mhz-transducer | 1 |
80 | micro/macro-electrodes | 1 |
81 | milligrammes | 1 |
82 | ml/yrs | 1 |
83 | mm/1 | 1 |
84 | months'duration | 1 |
85 | months-with | 1 |
86 | monts | 1 |
87 | n-peptide | 1 |
88 | name-to | 1 |
89 | neolignanamides | 1 |
90 | ngmol/l | 1 |
91 | non-hyperinflators | 1 |
92 | nutrients-sodium | 1 |
93 | oligo-hydroxyalkanoates | 1 |
94 | oocyts | 1 |
95 | options.. | 1 |
96 | orang-utans | 1 |
97 | peaks/day | 1 |
98 | people/household | 1 |
99 | phencyclidines | 1 |
100 | picocuries | 1 |
101 | probe-mixes | 1 |
102 | proteases-alcalase | 1 |
103 | pshsp70 | 1 |
104 | psoralen+ultraviolet | 1 |
105 | pulli | 1 |
106 | p⩽0.014 | 1 |
107 | questions/procedures | 1 |
108 | rap2s | 1 |
109 | rct/ccts | 1 |
110 | recementations | 1 |
111 | rifleman | 1 |
112 | sek8,400 | 1 |
113 | selenoaminoacids | 1 |
114 | site-types | 1 |
115 | sites-pmc | 1 |
116 | study-periods | 1 |
117 | sub-models | 1 |
118 | tetrachlorobenzenes | 1 |
119 | thimes | 1 |
120 | time-stages | 1 |
121 | time=68.2.2 | 1 |
122 | tjgies | 1 |
123 | treatments-brc-gly | 1 |
124 | trials-by | 1 |
125 | trials.ampicillin | 1 |
126 | trials.of | 1 |
127 | tv-channels | 1 |
128 | under-studies | 1 |
129 | uremias | 1 |
130 | video-calls | 1 |
131 | wase | 1 |
132 | watt/m2 | 1 |
133 | weeks+placebo-sc | 1 |
134 | weeks-old | 1 |
135 | weeks.on | 1 |
136 | weeks.patients | 1 |
137 | yardings | 1 |
138 | years-showed | 1 |
139 | years.on | 1 |
140 | £187,000 | 1 |
141 | £20,876 | 1 |
142 | £344.50 | 1 |
143 | °c-rely | 1 |
144 | α-l-fucosidases | 1 |
145 | €3683 | 1 |
146 | €439 | 1 |
1 | 0-1+ | 1 |
2 | 0.05/0.07 | 1 |
3 | 0.06/0.07 | 1 |
4 | 10-40-fold | 1 |
5 | 117.1j | 1 |
6 | 28-daycycles | 1 |
7 | 28.6-fold | 1 |
8 | 64·5 | 1 |
9 | 898-positive | 1 |
10 | acupuncturist-delivered | 1 |
11 | appendicovesicostomies | 1 |
12 | applications-a-day | 1 |
13 | arms.arm | 1 |
14 | aul | 3 |
15 | badwas | 1 |
16 | bolus/20- | 1 |
17 | broodstocks | 1 |
18 | camcorders | 1 |
19 | cans/pouches | 2 |
20 | cebidae | 1 |
21 | cef-patients | 1 |
22 | cis-epoxides | 1 |
23 | classifications-values | 1 |
24 | clpb/hsp100s | 1 |
25 | co5c | 1 |
26 | conditions-mahjong | 1 |
27 | cost-levels | 1 |
28 | cp-cases | 1 |
29 | cycle/degree | 1 |
30 | dabatases | 1 |
31 | denvs | 4 |
32 | dimensions-level | 1 |
33 | disulfide-bridges | 1 |
34 | domains-nad-binding | 1 |
35 | drinks/two | 1 |
36 | drugs/combination | 1 |
37 | départements | 1 |
38 | ep-hsps | 1 |
39 | euro2-6 | 1 |
40 | euro292 | 1 |
41 | fhps | 1 |
42 | g/head | 1 |
43 | g/kg-produced | 1 |
44 | g/twice | 1 |
45 | gbhsps | 1 |
46 | geq/l | 1 |
47 | gigatons | 1 |
48 | gm/hr | 1 |
49 | goats/group | 1 |
50 | group-meetings | 2 |
51 | groups-calcitriol | 1 |
52 | groups.patients | 1 |
53 | groups/blocks | 1 |
54 | hamuli | 1 |
55 | homeostasis-was | 1 |
56 | hsa-rois | 1 |
57 | hsp60s | 1 |
58 | hundred-fold | 5 |
59 | hydroxy-3-methylglutaryl-coenzyme | 1 |
60 | hyperthyroidisms | 2 |
61 | ifets | 3 |
62 | inhibitor-meets | 1 |
63 | job-agencies | 1 |
64 | kg/calf | 2 |
65 | kg/heifer | 2 |
66 | kg/m3-d. | 1 |
67 | kilobits | 1 |
68 | kj/kg/d | 2 |
69 | l/head | 3 |
70 | macronutrient-balanced | 1 |
71 | mailers | 1 |
72 | meq/litre | 2 |
73 | mestrua | 1 |
74 | mhz-transducer | 1 |
75 | micro/macro-electrodes | 1 |
76 | milligrammes | 1 |
77 | ml/yrs | 1 |
78 | mm/1 | 1 |
79 | months'duration | 1 |
80 | months-with | 1 |
81 | monts | 1 |
82 | ms/cm | 2 |
83 | n-peptide | 1 |
84 | name-to | 1 |
85 | neolignanamides | 1 |
86 | ngmol/l | 1 |
87 | non-hyperinflators | 1 |
88 | nutrients-sodium | 1 |
89 | oligo-hydroxyalkanoates | 1 |
90 | oocyts | 1 |
91 | options.. | 1 |
92 | orang-utans | 1 |
93 | peaks/day | 1 |
94 | people/household | 1 |
95 | phencyclidines | 1 |
96 | picocuries | 1 |
97 | probe-mixes | 1 |
98 | proteases-alcalase | 1 |
99 | pshsp70 | 1 |
100 | psoralen+ultraviolet | 1 |
101 | pulli | 1 |
102 | p⩽0.014 | 1 |
103 | questions/procedures | 1 |
104 | rap2s | 1 |
105 | rct/ccts | 1 |
106 | recementations | 1 |
107 | rifleman | 1 |
108 | sek8,400 | 1 |
109 | selenoaminoacids | 1 |
110 | site-types | 1 |
111 | sites-pmc | 1 |
112 | study-periods | 1 |
113 | sub-models | 1 |
114 | tetrachlorobenzenes | 1 |
115 | thimes | 1 |
116 | time-stages | 1 |
117 | time=68.2.2 | 1 |
118 | times | 18,938 |
119 | times-per-week | 2 |
120 | tjgies | 1 |
121 | treatments-brc-gly | 1 |
122 | treatments/day | 2 |
123 | trials-by | 1 |
124 | trials.ampicillin | 1 |
125 | trials.of | 1 |
126 | tv-channels | 1 |
127 | uacrs | 3 |
128 | under-studies | 1 |
129 | uremias | 1 |
130 | video-calls | 1 |
131 | wase | 1 |
132 | watt/m2 | 1 |
133 | weeks+placebo-sc | 1 |
134 | weeks-old | 1 |
135 | weeks.on | 1 |
136 | weeks.patients | 1 |
137 | yardings | 1 |
138 | years-showed | 1 |
139 | years.on | 1 |
140 | £187,000 | 1 |
141 | £20,876 | 1 |
142 | £344.50 | 1 |
143 | °c-rely | 1 |
144 | α-l-fucosidases | 1 |
145 | €3683 | 1 |
146 | €439 | 1 |
1 | 0-1+ | 1 |
2 | bolus/20- | 1 |
3 | options.. | 1 |
4 | kg/m3-d. | 1 |
5 | £187,000 | 1 |
6 | sek8,400 | 1 |
7 | £344.50 | 1 |
8 | pshsp70 | 1 |
9 | mm/1 | 1 |
10 | time=68.2.2 | 1 |
11 | euro292 | 1 |
12 | watt/m2 | 1 |
13 | €3683 | 1 |
14 | p⩽0.014 | 1 |
15 | 64·5 | 1 |
16 | euro2-6 | 1 |
17 | £20,876 | 1 |
18 | 0.05/0.07 | 1 |
19 | 0.06/0.07 | 1 |
20 | €439 | 1 |
21 | mestrua | 1 |
22 | co5c | 1 |
23 | sites-pmc | 1 |
24 | weeks+placebo-sc | 1 |
25 | kj/kg/d | 2 |
26 | g/head | 1 |
27 | l/head | 3 |
28 | macronutrient-balanced | 1 |
29 | g/kg-produced | 1 |
30 | acupuncturist-delivered | 1 |
31 | years-showed | 1 |
32 | weeks-old | 1 |
33 | 10-40-fold | 1 |
34 | 28.6-fold | 1 |
35 | hundred-fold | 5 |
36 | people/household | 1 |
37 | cebidae | 1 |
38 | g/twice | 1 |
39 | n-peptide | 1 |
40 | cycle/degree | 1 |
41 | hydroxy-3-methylglutaryl-coenzyme | 1 |
42 | meq/litre | 2 |
43 | proteases-alcalase | 1 |
44 | wase | 1 |
45 | 898-positive | 1 |
46 | kg/calf | 2 |
47 | trials.of | 1 |
48 | domains-nad-binding | 1 |
49 | conditions-mahjong | 1 |
50 | months-with | 1 |
51 | pulli | 1 |
52 | hamuli | 1 |
53 | 117.1j | 1 |
54 | times-per-week | 2 |
55 | ngmol/l | 1 |
56 | geq/l | 1 |
57 | dimensions-level | 1 |
58 | groups-calcitriol | 1 |
59 | aul | 3 |
60 | ms/cm | 2 |
61 | arms.arm | 1 |
62 | nutrients-sodium | 1 |
63 | rifleman | 1 |
64 | trials.ampicillin | 1 |
65 | weeks.on | 1 |
66 | years.on | 1 |
67 | drugs/combination | 1 |
68 | months'duration | 1 |
69 | name-to | 1 |
70 | drinks/two | 1 |
71 | goats/group | 1 |
72 | mhz-transducer | 1 |
73 | kg/heifer | 2 |
74 | gm/hr | 1 |
75 | clpb/hsp100s | 1 |
76 | hsp60s | 1 |
77 | rap2s | 1 |
78 | uremias | 1 |
79 | homeostasis-was | 1 |
80 | badwas | 1 |
81 | selenoaminoacids | 1 |
82 | study-periods | 1 |
83 | neolignanamides | 1 |
84 | cis-epoxides | 1 |
85 | micro/macro-electrodes | 1 |
86 | time-stages | 1 |
87 | disulfide-bridges | 1 |
88 | cans/pouches | 2 |
89 | job-agencies | 1 |
90 | under-studies | 1 |
91 | tjgies | 1 |
92 | appendicovesicostomies | 1 |
93 | picocuries | 1 |
94 | 28-daycycles | 1 |
95 | thimes | 1 |
96 | times | 18,938 |
97 | milligrammes | 1 |
98 | tetrachlorobenzenes | 1 |
99 | phencyclidines | 1 |
100 | site-types | 1 |
101 | questions/procedures | 1 |
102 | cp-cases | 1 |
103 | α-l-fucosidases | 1 |
104 | dabatases | 1 |
105 | oligo-hydroxyalkanoates | 1 |
106 | classifications-values | 1 |
107 | probe-mixes | 1 |
108 | yardings | 1 |
109 | group-meetings | 2 |
110 | hsa-rois | 1 |
111 | groups/blocks | 1 |
112 | broodstocks | 1 |
113 | sub-models | 1 |
114 | tv-channels | 1 |
115 | cost-levels | 1 |
116 | video-calls | 1 |
117 | hyperthyroidisms | 2 |
118 | orang-utans | 1 |
119 | recementations | 1 |
120 | gigatons | 1 |
121 | fhps | 1 |
122 | ep-hsps | 1 |
123 | gbhsps | 1 |
124 | uacrs | 3 |
125 | camcorders | 1 |
126 | mailers | 1 |
127 | non-hyperinflators | 1 |
128 | ml/yrs | 1 |
129 | rct/ccts | 1 |
130 | inhibitor-meets | 1 |
131 | ifets | 3 |
132 | kilobits | 1 |
133 | cef-patients | 1 |
134 | weeks.patients | 1 |
135 | groups.patients | 1 |
136 | départements | 1 |
137 | monts | 1 |
138 | oocyts | 1 |
139 | denvs | 4 |
140 | psoralen+ultraviolet | 1 |
141 | applications-a-day | 1 |
142 | peaks/day | 1 |
143 | treatments/day | 2 |
144 | trials-by | 1 |
145 | °c-rely | 1 |
146 | treatments-brc-gly | 1 |